<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04747808</url>
  </required_header>
  <id_info>
    <org_study_id>LL-BMT10001</org_study_id>
    <nct_id>NCT04747808</nct_id>
  </id_info>
  <brief_title>Study of LL-BMT1 in Patients With Elevated Intraocular Pressure</brief_title>
  <official_title>A Phase 2a Study of Safety, Tolerability, and Efficacy of Drug-Delivering Contact Lens LL-BMT1 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MediPrint Ophthalmics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MediPrint Ophthalmics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, Phase 2a clinical study of LL-BMT1 in patients with primary open-angle&#xD;
      glaucoma and ocular hypertension. Study subjects will be treated for 7 days with a single&#xD;
      dose of LL-BMT1.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 8, 2021</start_date>
  <completion_date type="Actual">February 16, 2021</completion_date>
  <primary_completion_date type="Actual">February 16, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, non-comparative</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event rate</measure>
    <time_frame>Day 7</time_frame>
    <description>Number of subjects with adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IOP elevation</measure>
    <time_frame>Day 7</time_frame>
    <description>Number of subjects with IOP elevation &gt;= 5 mm Hg in study eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOP changes</measure>
    <time_frame>Days 1-7</time_frame>
    <description>Mean change in IOP from baseline in study eye (mm Hg)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>LL-BMT1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 4 extended-wear contact lens printed with bimatoprost</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LL-BMT1</intervention_name>
    <description>Drug-printed contact lens in both eyes</description>
    <arm_group_label>LL-BMT1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, at least 18 years of age at the Screening Visit&#xD;
&#xD;
          -  Diagnosed with primary open-angle glaucoma or ocular hypertension in both eyes&#xD;
&#xD;
          -  At least one eye (called the study eye) must have an untreated intraocular pressure&#xD;
             between 22 mmHg and 34 mmHg (inclusive) as measured at 9 am during the Baseline Visit.&#xD;
&#xD;
          -  Best corrected visual acuity of Early Treatment Diabetic Retinopathy Study of 50&#xD;
             letters or better&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Glaucoma or optic neuropathy due to anything other than above noted reasons&#xD;
             Cup-to-disc ratio of &gt;0.8 in either eye&#xD;
&#xD;
          -  Corneal thickness &lt;480 or &gt;620 Î¼m&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eye Research Foundatoin</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Prostaglandin</keyword>
  <keyword>Intraocular pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

